What is the 13F Pro Quality Score for ENVB?

13F Pro ranks Enveric Biosciences, Inc. (ENVB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENVB's current score at https://13fpro.ai/research/ENVB (free sign-up required for the full ranking).

Where does 13F Pro source ENVB data?

All Enveric Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Enveric Biosciences, Inc. files with the SEC under CIK 890821. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENVB in?

Enveric Biosciences, Inc. (ENVB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ENVB research updated on 13F Pro?

ENVB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Enveric Biosciences, Inc.(ENVB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 890821 ENVB stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $48.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ENVB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Enveric Biosciences, Inc. (ENVB), a Healthcare sector company. ENVB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $48.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Enveric Biosciences, Inc. reports net income of $-1.6M, free cash flow of $-2.3M. Top institutional holders of ENVB by reported 13-F value include GEODE CAPITAL MANAGEMENT,, AdvisorShares Investments, UBS Group AG, based on the most recent SEC filings. ENVB trades on the Nasdaq exchange and files with the SEC under CIK 890821. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENVB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Enveric Biosciences, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-1.6M

Free Cash Flow

Q1 2026

$-2.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY21 —FY23 —FY24 —FY25 —

Net Income

+26.0% YoY

$12.1MFY 2025

FY21 $-49.0MFY23 $17.5MFY24 $9.6MFY25 $12.1M

Operating Income

+8.9% YoY

$-8.8MFY 2025

FY21 $-64.6MFY23 $-16.4MFY24 $-9.6MFY25 $-8.8M

EPS (Diluted)

-218213.3% YoY

$-36.24FY 2025

FY21 —FY23 $-0.01FY24 $-0.02FY25 $-36.24

Total Assets

+65.3% YoY

$5.1MFY 2025

FY21 $26.7MFY23 $4.3MFY24 $3.1MFY25 $5.1M

Total Debt

—FY 2025

FY21 —FY23 —FY24 —FY25 —

Op. Cash Flow

-5.4% YoY

$-8.1MFY 2025

FY21 $-11.5MFY23 $-14.1MFY24 $-7.7MFY25 $-8.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2018
Revenue	—	—	—	—	—	$43.0M
Net Income	$12.1M +26.0%	$9.6M -45.1%	$17.5M +135.7%	$-49.0M -613.5%	$-6.9M +59.4%	$-16.9M
Operating Income	$-8.8M +8.9%	$-9.6M +41.4%	$-16.4M +74.5%	$-64.6M -1050.4%	$-5.6M +21.4%	$-7.1M
EPS (Diluted)	$-36.24 -218213.3%	$-0.02 -88.6%	$-0.01	—	—	$-0.45
Total Assets	$5.1M +65.3%	$3.1M -28.3%	$4.3M -83.9%	$26.7M +552.2%	$4.1M -86.2%	$29.6M
Total Debt	—	—	—	—	—	$5.2M
Operating Cash Flow	$-8.1M -5.4%	$-7.7M +45.2%	$-14.1M -23.0%	$-11.5M -194.6%	$-3.9M -51.6%	$-2.6M

AI Insight: ENVB Financial Trends

Pre-revenue biotech burning $2–3M per quarter with equity oscillating between $2–5M; no clear path to profitability visible.

• Operating cash burn stable at $1–3M/quarter over 9 quarters; no acceleration or deceleration evident.

• Equity base fluctuates $2–5M range; Q1 2026 recovered to $5M from Q2 2025 trough of $2M.

⚠ No revenue reported across all 8 quarters; continued operating losses with negative OCF signal ongoing cash depletion.

⚠ Equity volatility ($2–5M swings) suggests dilutive financing or asset sales; runway sustainability unclear.

AI Insight: ENVB Ratio Trends

Enveric remains deeply unprofitable with ROE deteriorating to -129.1% in Q1 2026, suggesting cash burn and negative shareholder returns.

• ROE worsened from -139.1% in Q2 2024 to -129.1% in Q1 2026, indicating persistent net losses relative to equity base.

• Only ROE and ROA data available across periods; operating margins, net margins, ROIC, and leverage ratios remain unreported.

⚠ Sustained negative ROE signals ongoing cash burn. Monitor quarterly losses and runway to profitability or funding events.

⚠ Data gaps (Q3 2024–Q4 2025) limit visibility into operating trends; clarify reporting timing and operational milestones.

Get alerted when ENVB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Enveric Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENVB

GEODE CAPITAL MANAGEMENT, LLC
$62.4K32,149 sh
AdvisorShares Investments LLC
$32.9K16,974 sh
UBS Group AG
$7.0K3,612 sh
Tower Research Capital LLC (TRC)
$2.1K1,103 sh
JONES FINANCIAL COMPANIES LLLP
$1.9K1,000 sh
SBI Securities Co., Ltd.
$161.0083 sh
BlackRock, Inc.
$99.0051 sh
DANSKE BANK A/S
$2.001 sh
GROUP ONE TRADING, L.P.
$2.001 sh
NATIONAL BANK OF CANADA /FI/
$2.001 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$62.4K	32,149
AdvisorShares Investments LLC	$32.9K	16,974
UBS Group AG	$7.0K	3,612
Tower Research Capital LLC (TRC)	$2.1K	1,103
JONES FINANCIAL COMPANIES LLLP	$1.9K	1,000
SBI Securities Co., Ltd.	$161.00	83
BlackRock, Inc.	$99.00	51
DANSKE BANK A/S	$2.00	1
GROUP ONE TRADING, L.P.	$2.00	1
NATIONAL BANK OF CANADA /FI/	$2.00	1

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENVB on your watchlist

Track score changes the day Enveric Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENVB a good stock to buy?

13F Pro's AI-powered analysis of Enveric Biosciences, Inc. (ENVB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENVB are available on the ENVB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ENVB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENVB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Enveric Biosciences, Inc.'s investment landscape.